Advaxis to Hold Business Update Conference Call on June 25, 2015
PRINCETON, N.J., June 19, 2015 /PRNewswire/ -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announces that its management team will host a corporate business update conference call and webcast to review recent accomplishments and key near-term milestones. Details of the call are below:
| Advaxis Conference Call & Webcast – Business Update |
||
| Date: |
Thursday, June 25, 2015 |
|
| Time: |
8:30am ET |
|
| Domestic Toll Free Dial-In: |
888-401-4669 |
|
| International Dial-In: |
719-325-2458 |
|
| Conference Passcode: |
7209396 |
|
| Live Webcast: |
||
| Replay: |
Available through July 9 at the URL above |
|
| Domestic Dial-In: |
877-870-5176 |
|
| International Dial In: |
858-384-5517 |
|
| Replay Passcode: |
7209396 |
|
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm Technology immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted Advaxis orphan drug designation for each of these three indications. For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.
Forward-Looking Statements
This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS-HPV. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
SOURCE Advaxis, Inc.
Share this article